Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice
Theoretically, the subunit herpes zoster vaccine Shingrix<sup>TM</sup> could be used as a varicella vaccine that avoids the risk of developing shingles from vaccination, but bedside mixing strategies and the limited supply of the adjuvant component QS21 have made its application economic...
Main Authors: | Han Cao, Yunfei Wang, Ning Luan, Cunbao Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/4/310 |
Similar Items
-
Swiss recommendations for the management of varicella zoster virus infections
by: R Agosti
Published: (2007-05-01) -
The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study
by: Alessia Melegaro, et al.
Published: (2018-07-01) -
Varicella zoster virus-associated morbidity and mortality in Africa – a systematic review
by: Hannah Hussey, et al.
Published: (2017-11-01) -
Herpes Zoster Burden of Disease and Clinical Management in Turkey: A Comprehensive Literature Review
by: Selim Badur, et al.
Published: (2023-08-01) -
Understanding the role of exogenous boosting in modeling varicella vaccination
by: Sandra E. Talbird, et al.
Published: (2018-11-01)